NCT01692691

Dacarbazine and Carmustine in Metastatic Melanoma

Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With Neulasta® Support in Previously Treated Metastatic Melanoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Western Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.

Detailed description

In this phase II trial, patients with stage IV melanoma will be treated with dacarbazine and carmustine commonly used in this cancer, but given using a schedule that might theoretically improve on this combination. Patients on this study will be assessed in terms of toxicity, response rate, median duration of response, median time to disease progression, and median survival.

Conditions

• Melanoma Metastatic

Interventions

Type	Name	Description
DRUG	Dacarbazine	Dacarbazine IV - Day 1
DRUG	Carmustine	Carmustine IV- Day 2
DRUG	Neulasta	Neulasta SC - Day 3

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2012-09-25
• Last updated: 2018-04-04
• Results posted: 2016-02-02

Locations

1 site across 1 country: United States